Leqvio, the first drug to treat high cholesterol, is available with two injections a year to effectively lower cholesterol

Inclisiran is currently the only small interfering RNA (siRNA) drug approved for use to lower LDL-C cholesterol.
the drug is currently under review by regulators such as the FDA.
addition, Inclisiran's "bad cholesterol" levels can be reduced by only twice a year after initial treatment in the first and third months, which is expected to address long-term compliance.
▌ "behind cardiovascular disease": "Bad Cholesterol" good doctors say LDL cholesterol, also known as "bad cholesterol," is a risk factor for atherosclerosis.
an accidental rupture of atherosclerotic plaque can cause atherosclerosis cardiovascular disease (ASCVD), such as a heart attack or stroke.
, cardiovascular disease remains the leading cause of death worldwide, with ASCVD accounting for more than 85% of all cardiovascular disease deaths.
treatment for cardiovascular disease is dominated by statins, but 80 percent of high-risk patients still do not reach the best level of LDL-C recommended by the guidelines, and they urgently need more innovative therapies.
▌siRNA drugs: Inclisiran Inclisiran is a pioneering siRNA drug that continuously and effectively reduces LDL-C levels and can be used in patients with acute and heterochemic hypercholesterolemia (HeFH) such as atherosclerosis (ASCVD), ASCVD, which are the leading causes of heart attack, stroke, and may eventually lead to death.
Inclisiran binds to mRNA that encodes the PCSK9 protein, reducing mRNA levels through RNA interference and preventing the liver from producing PCSK9 protein, thereby enhancing the liver's ability to remove LDL-C from the blood and reducing LDL-C levels.
, although several PCSK9 inhibitors have been approved by the FDA, Inclisiran's advantage is that patients only need to receive two subsurfic injections a year to control cholesterol levels, an easy treatment option.
Inclisiran has been approved for the treatment of primary hypercholesterolemia in adults (including hemolytic familial and non-family) or mixed blood lipid abnormalities as an ancillary treatment of the diet: for patients who still do not meet LDL-C levels after statin treatment with the maximum to-to-do dose, statins or other antilipidation therapies can be used in combination with statins or other antilipidation therapies alone.
▌ clinical data, significantly reducing the risk of ASCVD in orION-9, ORION-10 and ORION-11 series of experiments, Inclisiran fat reduction durability, effectiveness and safety have been verified.
ORION-9 trials were conducted in patients with familial hypercholesterolemia (FH) and ORION-10 and ORION-11 in people at high risk of ASCVD or ASCVD.
results have been published in the New England Journal of Medicine.
family hypercholesterolemia (HeFH) is a rare genetic disorder that causes high levels of LDL-C and increases the risk of early oncercation of ASCVD.
ORION-9 trial was conducted in 482 adult patients with hemp subtype FH, who were randomly grouped and given subsurgery injections of Inclisiran 300 mg or placebo on days 1, 90, 270 and 450, respectively.
results of the trial showed that LDL-C levels in the Inclisiran group decreased by 39.7% compared to the baseline at 17 months, compared with 8.2% in the placebo group, and the difference in LDL-C levels was 47.9%.
and in all genotype FH patients, LDL-C was significantly reduced.
treatment of ORION-10 patients at high risk of ASCVD or ASCVD included 1,561 patients with atherosclerotic cardiovascular disease (ASCVD), while the ORION-11 trial included 1,414 ASCVD patients and 203 people at risk of ASCVD.
in ORION-10 and ORION-11 trials, participants had higher statin use rates of 89% and 95%, respectively, and the majority of patients received high-intensity statins, 68% and 78%, respectively.
the trial, the average cholesterol in patients was 2.71 mmol/L and 2.73 mmol/L, respectively.
results showed that LDL-C levels in the ORION-10 trial group were 52.3 percent lower in the 17th month and 49.9 percent lower in the ORION-11 trial group compared to the placebo.
, cardiovascular disease remains the leading cause of death in humans.
and Inclisiran, the first siRNA drug in the cardiovascular field, has great potential to improve treatment outcomes in patients with cardiovascular disease by continuously and effectively reducing LDL-C levels.
reference source: